North America Proteomics Market worth $25.62 billion by 2030
the report "North America Proteomics Market by Instrumentation (Mass Spectrometry, HPLC, Electrophoresis, Protein Microarray), Reagent (Immunoassay), Service (Purification, Bioinformatics), Software, Application (Clinical, Drug Discovery)- Forecast to 2030", is projected to grow from USD 14.11 billion in 2025 and to reach USD 25.62 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 12.7% during the forecast period.
Browse 270 market data Tables and 30 Figures spread through 300 Pages and in-depth TOC on "North America Proteomics Market by Instrumentation (Mass Spectrometry, HPLC, Electrophoresis, Protein Microarray), Reagent (Immunoassay), Service (Purification, Bioinformatics), Software, Application (Clinical, Drug Discovery)- Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/north-america-proteomics-market-55573280.html
The North America Proteomics market is experiencing growth, driven by several key factors, including Strong funding & public-private programs and growing Clinical proteomics momentum.
The spectroscopy segment accounted for the largest share of the North America Proteomics market, by technique, in 2024.
By technology, the proteomics market is segmented into spectroscopy, chromatography, electrophoresis, protein microarrays, X-ray crystallography, surface plasmon resonance, protein fractionation, and other technologies. The spectroscopy segment is further segmented into mass spectrometry, NMR spectroscopy, and CD spectroscopy. The chromatography segment is further divided into HPLC, ion chromatography, affinity chromatography, and supercritical fluid chromatography. In 2024, the spectroscopy segment accounted for the largest share of the technology segment of the proteomics market, followed by the chromatography segment. The dominance of the spectroscopy segment is attributable to the high accuracy and sensitivity of spectroscopy techniques for complex protein structures, as well as the increased use of spectroscopy in biomarker discovery, drug development, and clinicaldiagnostics.d
In 2024, the Clinical diagnostics segment is expected to be the fastest-growing in the North America proteomics market, by application.
By application, the market is divided into clinical diagnostics, drug discovery and development, and other applications. Of these, the clinical diagnostics segment held the largest share in 2023, owing to the growing use of proteomics in precision medicine and personalized healthcare. Rising demand for proteomic technologies to identify and validate disease-associated biomarkers has further supported this segment. These biomarkers are crucial for early disease diagnosis, prognosis determination, and ongoing monitoring of disease progression, thereby strengthening the high adoption of proteomics in clinical diagnostics.
The US accounted for the largest regional share in the North America proteomics market in 2024.
The North American proteomics market is segmented into the US and Canada. A large base of biotechnology and pharmaceutical companies, heavy federal and private R&D funding, and a concentration of leading instrument and reagent manufacturers make the United States dominant in the North American proteomics market. Its strong adoption in precision medicine, oncology, and drug discovery further reinforces this country's leadership, with sustained venture capital and strategic acquisitions.
Key players in the North America proteomics market include Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Agilent Technologies (US), Bio-Rad Laboratories (US), Revvity (US), Illumina Inc. (US), Promega Corporation (US), and Seer Inc. (US).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the North America Proteomics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
